EAACI guideline: Anaphylaxis (2021 update)

Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Allergy (Copenhagen) Jg. 77; H. 2; S. 357 - 377
Hauptverfasser: Muraro, Antonella, Worm, Margitta, Alviani, Cherry, Cardona, Victoria, Dunngalvin, Audrey, Garvey, Lene Heise, Riggioni, Carmen, de Silva, Debra, Angier, Elizabeth, Arasi, Stefania, Bellou, Abdelouahab, Beyer, Kirsten, Bijlhout, Diola, Bilò, Maria Beatrice, Bindslev-Jensen, Carsten, Brockow, Knut, Fernandez-Rivas, Montserrat, Halken, Susanne, Jensen, Britt, Khaleva, Ekaterina, Michaelis, Louise J, Oude Elberink, Hanneke N G, Regent, Lynne, Sanchez, Angel, Vlieg-Boerstra, Berber J, Roberts, Graham
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Wiley 01.02.2022
Schlagworte:
Life Sciences
guidelines
anaphylaxis
children
adults
ISSN:0105-4538, 1398-9995
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Anaphylaxis is a clinical emergency which all healthcare professionals need to be able to recognize and manage. The European Academy of Allergy and Clinical Immunology Anaphylaxis multidisciplinary Task Force has updated the 2014 guideline. The guideline was developed using the AGREE II framework and the GRADE approach. The evidence was systematically reviewed and recommendations were created by weighing up benefits and harms. The guideline was peer-reviewed by external experts and reviewed in a public consultation. The use of clinical criteria to identify anaphylaxis is suggested with blood sampling for the later measurement of tryptase. The prompt use of intramuscular adrenaline as first-line management is recommended with the availability of adrenaline autoinjectors to patients in the community. Pharmacokinetic data should be provided for adrenaline autoinjector devices. Structured, comprehensive training for people at risk of anaphylaxis is recommended. Simulation training and visual prompts for healthcare professionals are suggested to improve the management of anaphylaxis. It is suggested that school policies reflect anaphylaxis guidelines. The evidence for the management of anaphylaxis remains mostly at a very low level. There is an urgent need to prioritize clinical trials with the potential to improve the management of patients at risk of anaphylaxis.
ISSN:0105-4538
1398-9995
DOI:10.1111/all.15032